Sun Pharma slumps, heads towards biggest fall ever

MUMBAI (Reuters) - Shares in Sun Pharmaceutical Industries
Analysts say results warning can cut FY16 consensus earnings estimates by 8-10 percent as company struggles to fix manufacturing problems at Ranbaxy Laboratories
(Reporting by Abhishek Vishnoi; Editing by Gopakumar Warrier)
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 21 2015 | 10:38 AM IST
